

BIOCRYST PHARMACEUTICALS INC  
Form 8-K/A  
August 04, 2011

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K/A

(Amendment No. 1)

### CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 4, 2011

## BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or other jurisdiction

of incorporation)

000-23186  
(Commission

File Number)

4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703

62-1413174  
(IRS Employer

Identification #)

Edgar Filing: BIOCRYST PHARMACEUTICALS INC - Form 8-K/A

(Address of Principal Executive Office)

(919) 859-1302

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 210.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02 Results of Operations and Financial Condition.**

BioCryst Pharmaceuticals, Inc. (the Company) issued a news release on August 4, 2011 (the News Release) regarding its results of operations and financial condition for the second quarter ended June 30, 2011. A copy of the News Release was furnished as Exhibit 99.1 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on August 4, 2011 (the Initial 8-K Filing).

The Company is filing this Amendment No. 1 to the Initial 8-K Filing (this Amendment) solely to correct a typographical error contained in the News Release in the sixth paragraph under the heading Second Quarter Financial Results. Specifically, the second sentence of that paragraph should have read: Net operating cash use for the recent quarter was \$3.7 million and year to date was \$14.9 million. This Amendment is being filed to make this correction. Other than correcting this typographical error, all other information included in the Initial 8-K filing is unchanged. Attached as Exhibit 99.1 and incorporated herein by reference is a copy of the corrected News Release.

**Item 7.01 Regulation FD Disclosure.**

The information furnished on Exhibit 99.1 is incorporated by reference under this Item 7.01 as if fully set forth herein.

The information furnished is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Corrected Press Release dated August 4, 2011 entitled Correction - BioCryst Provides Corporate Update and Reports Second Quarter 2011 Financial Results.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BioCryst Pharmaceuticals, Inc.**

By: /s/ Alane Barnes  
Alane Barnes  
General Counsel, Corporate Secretary

Dated: August 4, 2011

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Corrected Press Release dated August 4, 2011 entitled Correction - BioCryst Provides Corporate Update and Reports Second Quarter 2011 Financial Results.